Search
Rallybio Corp
RLYBAdd to Watchlist
15.700USD
-0.230-1.44%
Close 06/23, 16:00（ET）Quotes delayed by 15 min
83.18MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-23The current earnings forecast score of Rallybio Corp is 6.00, ranking 329 out of 389 in the Biotechnology & Medical Research industry. The average price target is 1.00, with a high of 1.00 and a low of 1.00.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
8.000
Target Price
+6.10%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Rallybio Corp
RLYB
1
Beigene Ltd
ONC
27
Ionis Pharmaceuticals Inc
IONS
27
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Rallybio Corp's price target?
Analysts forecast that Rallybio Corp's price target is USD 1.00, with the highest forecast at USD 1.00 and the lowest forecast at USD 1.00.
How have Rallybio CorpRLYB's recent earnings per share performed?
The market expectation was USD -1.46, while Rallybio CorpRLYB's earnings per share (EPS) for the previous quarter was USD -1.03. EPS for the next quarter is expected at USD -1.28.
What is the analyst rating for Rallybio Corp?
Based on the ratings of Rallybio Corp's stock from 1 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.
